LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...

With its new FDA approval, Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody, has become the first prophylactic treatment for patients with hemophilia A with or ...

There are two main types of hemophilia - Hemophilia A (due to factor VIII deficiency) and Hemophilia B (due to factor IX deficiency). They are clinically almost identical and are associated with ...

Factor deficiency or inhibition. The possible causes of the isolated prolonged aPTT in this case include factor deficiencies and factor inhibitors. Prolongation of both the PT and aPTT suggests ...

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF XTEN Fusion Protein], a first-in-class, ...

Marstacimab is the first subcutaneous option for hemophilia B, reducing reliance on frequent IV infusions and improving patient quality of life. The phase 3 BASIS trial showed marstacimab reduced ...

PATIENTS with factor VIII deficiency and prolonged skin bleeding time (von Willebrand's syndrome) who receive fresh blood or plasma from normal donors or from patients with hæmophilia A with very low ...

Rare clotting factor deficiencies are a collection of bleeding disorders associated with issues with clotting factors. These conditions are inherited and target the proteins in the blood that control ...